“FDA Gives Nod to Mirvetuximab Soravtansine”, Cancer Discovery (2023)

Link to Publication:

https://aacrjournals.org/cancerdiscovery/article-abstract/13/1/8/712680/FDA-Gives-Nod-to-Mirvetuximab-SoravtansineFDA

Abstract: The FDA has granted accelerated approval to mirvetuximab soravtansine to treat patients with folate receptor alpha (FRα)–positive, platinum-resistant epithelial ovarian, primary peritoneal, and fallopian tube cancers. The FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay companion diagnostic device, which detects the FRα protein and could determine which patients will likely respond to the antibody–drug conjugate.